What I meant in yesterday note.

What I meant in yesterday note. That the GM’s business is extremely important we are seeing by the several indicators. Only ‘blaming’ my perseverance in acute business, the instinct that provide such smart ‘division’ with nothing (or what I get) – just meant one of many levels that can sober many of political, economic and strategic opponents hovering around me. Are too much ‘fat mouth’? To tap myself into another dimension and to answer correctly in this and not another way around – I’m writing. Writing about the subconscious staff. Many times of other people, which I can sense even before they do. The Stockholm environmental meeting for which “my” “Karlsson-on-the-Roof” awake me, even before the Sevran’s Lidl hostages happen. Before was dreaming in Ukrainian from Brussels with some guy with face of Charles the II jumping like a kangaroo out of window. More late I see his ‘promotion movie’ Karzai elections in the International Herald Tribune/The New York Times website. And I told you what: It’s all too much for me. Sincerely, it’s better try getting on with my own things, rather than becoming too involved in what isn’t my concern, and never will be. The raison d’être is exactly what I meant in yesterday note. And like always, more late I had proves who is accurately the shitty chi-Wawa. (Read the articles about Lykshin and the Ryazanov), than help me to find the synonyms for these medvedev, dvorkovitch and the million bands. More yet, after yesterday my “active participation” in UN-Iran Uranverein. Who you are – I insist for many years. You at least understood how unproductive area you are for me. Meaning of retirement, of pension, of the financial security plans – is blind spot for you. More yet, after yesterday, the yours, nor mine the “yellow syndicate” of ‘Tony здравствуй’.

Russians position for nanotech future. Russian pledges to spend billions in public funds to develop its nanotechnology industry are being treated cautiously by leading British technology companies. Published: 5:49PM BST 19 Oct 2009. RUSSIAN pledges to spend billions in public funds to develop its nanotechnology industry are being treated cautiously by leading British technology companies. President Dmitry Medvedev said the country will channel 318bn rubles (£6.3bn) into the development of a nanotech infrastructure to increase exports of products built in Russia using the technology. "We want to lead the process, and we have the intellectual potential, the organisational skills and the finance," he said. Oxford Instruments, a British nanotechnology company, said, however, that that it may take time for the cash to become available. Frazer Anderson, a business development director, from its Bristol-based plasma technology division, said: "Their timescales are a lot longer than ours. If they say $10bn, they probably will do that over the next 10 to 15 years." He added: "If you see big numbers it's excellent but the reality is that it does not always come to pass." However, Mr Anderson said his company had seen an increase in technology spending from governments worldwide as part of their fiscal stimulus packages. "We do see President Obama putting more into solar and solid-state lighting. We see that in China. India is on photovoltaics," he said. This trend had led to more demand for Oxford's equipment. The Plasma technology industry creates thin-film or nano-tech devices that are used in everything from the motion sensors in the Nintendo Wii games console to Osram light-emitting diode lights and pure research at institutes such as MIT and Harvard, and Max Planck in Germany. Oxford exports 90pc of what it sells and all its manufacturing is in the UK. It just sent £2m of equipment to Saudi Arabia's King Abdullah university of science and techology. Mr Anderson said that to win work in Russia, companies had to understand procurement. He said the country operates three buying houses for technology purchases. These have just been privatised but operate in a similar way to when they were state-owned. British companies keen to sell have to use an intermediary, which is licensed. However, these companies will only deal with Russian agents. "They influence things behind the scenes," said Mr Anderson.

Pfizer 3Q profit jumps 26 percent on cost cutting. Drugmaker Pfizer's 3Q profit jumps 26 percent on cost cuts; more expected with Wyeth deal done.On 1:12 pm EDT, Tuesday October 20, 2009. TRENTON, N.J. (AP) -- Drugmaker Pfizer Inc. on Tuesday posted a 26 percent jump in third-quarter profit despite the recession, as sharp cost cuts made up for a dip in sales. The maker of cholesterol fighter Lipitor, impotence treatment Viagra and smoking cessation drug Chantix slashed costs on everything from manufacturing and marketing to research and development to produce net income of $2.88 billion. That was up from $2.28 billion a year earlier, when the company had a big legal charge over improper promotion of its painkillers. New York-based Pfizer will keep cutting costs, now that it has completed the biggest drug industry deal of the year. The $68 billion acquisition of Wyeth last Thursday cements Pfizer's position atop the industry, and the combined company is expected to eliminate nearly 20,000 jobs by the time integration is complete. Pfizer has cut 6,500 jobs in 2009. Chief Executive Jeff Kindler told analysts the combined company has hit the ground running and will Chief Financial Officer Frank D'Amelio said in an interview Pfizer will continue investing in high-growth areas, particularly emerging markets. Pfizer faces direct generic competition to Lipitor late in 2011, when it will rapidly lose most of the drug's $12 billion-plus annual sales. That's about one-the fourth of all Pfizer revenue and was a key impetus for the Wyeth deal. "You're going to see a number of really high-impact medicines coming out of this portfolio over the next few years," said Pfizer's head of pharmaceutical research, Martin Mackay. In afternoon trading, shares of Pfizer rose 9 cents to $18.07.